// App-Quantinova.ai

891 : Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Pediatric Patients with Venous Thromboembolism

Researchers

Presenter

  • Daniel Rshammar

Principal Investigators

  • Fenglei Huang

  • Manuela Albisetti

  • Lisa Bomgaars

  • Elizabeth Chalmers

  • Matteo Luciani

  • Jacqueline Halton

  • Lesley Mitchell

  • David Joseph

  • Igor Tartakovsky

  • Savion Gropper

  • Martina Brueckmann

  • Leonardo R. Brandao

Medical Centers

  • Pharmetheus,Uppsala,Sweden

  • Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States

  • Hematology Department, University Children’s Hospital, Zürich, Switzerland

  • Department of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hematology/Oncology Department, Pediatric Hospital Bambino Gesù, Rome, Italy

  • University of Ottawa, Children's Hospital of Eastern Ontario, Ontario, Ontario, Canada

  • Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany

  • Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany

  • Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany

  • Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada

Locations

  • Sweden

  • United States

  • Switzerland

  • United Kingdom

  • Italy

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved